PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home »

Psychiatric Times. Vol. 24 No. 4
Pages: 1  2  3  
Next
 

Psychiatric Polypharmacy: The Good, the Bad, and the Ugly

By Steven J. Kingsbury, MD, PhD and Megan Leahy Lotito, PharmD, BCPP | April 1, 2007
Dr Kingsbury is chief of outpatient mental health at the VA Southern Nevada Healthcare System in Las Vegas and clinical professor of psychiatry in the department of Psychiatry and Behavioral Science at the University of Nevada. Dr Lotito is a clinical pharmacy specialist in psychiatry and director of the PGY1 pharmacy residency program at the VA Southern Nevada Healthcare System in Las Vegas. She is also assistant professor of pharmacy practice at the University of Southern Nevada College of Pharmacy. Dr Kingsbury reports that he is on the speakers' bureau for AstraZeneca, Bristol-Myers Squibb, Forest, Janssen, and Pfizer. Dr Lotito reports that she has no conflicts of interest concerning the subject matter of this article.

A great deal of data exists about the dangers of polypharmacy. Persons with psychiatric disorders experience increased risk for adverse drug interactions because of the great frequency with which multiple medications are used.1 Using multiple antipsychotics concomitantly has been associated with increased mortality in patients with schizophrenia.2 Reports of adverse psychiatric polypharmacy effects are abundant, including increased duration of hospital stay.3

In this article we define polypharmacy as the use of 2 or more medications of the same chemical class or with the same or similar pharmacological actions to treat the same condition or separate conditions. For example, prescribing thyroid medication to augment antidepressant response would be polypharmacy, while using thyroid medication to treat hypothyroidism, with concomitant antidepressant therapy for depression would not be considered polypharmacy (Table 1).

TABLE 1
General examples of polypharmacy
   
Aripiprazole + haloperidol(Drug information on haloperidol) for psychosis
Valproic acid + lamotrigine(Drug information on lamotrigine) for mood stabilization
Same chemical class to treat separate conditions
Clonazepam for anxiety + temazepam(Drug information on temazepam) for sleep
Risperidone for psychosis + low-dose quetiapine(Drug information on quetiapine) for anxiety
Same pharmacological action to treat the same condition
Diphenhydramine + temazepam for sleep
SSRI + nortriptyline(Drug information on nortriptyline) for depression
Same pharmacological action to treat separate conditions
SSRI for depression + bupropion for smoking cessation
SSRI for depression + low-dose trazodone for sleep
Similar pharmacological action to treat the same condition
Temazepam + zolpidem(Drug information on zolpidem) for sleep
Antidepressant + triiodothyronine or thyroxine for depression
Similar pharmacological action to treat separate conditions
Venlafaxine for depression + low-dose amitriptyline(Drug information on amitriptyline) for pain
Mirtazepine for depression + ondansetron for nausea

Although the use of multiple medications to treat different conditions is beyond the scope of this paper, it should be realized that there is a potential for problems any time multiple medications are used. As an example, cases of carbamazepine(Drug information on carbamazepine) toxicity have been reported when this mood stabilizer is used in combination with protease inhibitors for HIV because of the well-known CYP3A4 inhibition of this antiretro- viral class.4

A medication that treats the adverse effects of another agent would not be considered polypharmacy by this definition. For instance, using anticholinergic agents to treat extrapyramidal side effects of first-generation antipsychotics or the use of amiloride(Drug information on amiloride) to treat lithium(Drug information on lithium)-induced polyuria may be empirically based. However, the need for 2 medications might be avoided with the use of second-generation antipsychotics in the first example or valproic acid in the second example.

The term polypharmacy does not in itself suggest whether its use is warranted. Ideally, only one medication would be used to optimally treat a symptom or disorder. However, even a cursory review of the literature suggests that many, if not most, patients show suboptimal response to any one given agent. New medications more specifically target disease state symptoms and have improved side-effect profiles, making combination treatment strategies more attractive and possibly less daunting. The legitimate increase in pressures to help improve patient status has changed the standard for successful treatment in psychiatry; the bar has been raised.

Perhaps the best example of this phenomenon is in the treatment of depression. Response is no longer considered an acceptable goal—remission is now the clear end point for therapy. Multiple lines of evidence show that patients who only respond have a poorer quality of life and are more likely to relapse.5,6

There are certainly some well-researched uses of medication combinations. Even casual reflection shows that the number of possible medication combinations to treat any psychiatric condition is enormous. Surveys have found that the use of 4 or 5 medications simultaneously is not uncommon in the treatment of bipolar disorder7 or other psychiatric conditions.8,9 Given the overwhelming number of possible combinations, it is unlikely that more than a few of these will be researched.

Pages: 1  2  3  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





  • Sachs G, Grossman F, Okamoto A, et al. Risperidone plus mood stabilizer versus placebo plus mood stabilizer for acute mania of bipolar disorder: a double-blind comparison of efficacy and safety. Am J Psychiatry. 2002;159: 1146-1154.
  • Yatham LN, Paulsson B, Mullen J,Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004;24:599-606.


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • Grief and Depression: The Sages Knew the Difference
  • The Moral Struggles of Practicing Psychiatrists
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Journey of the Traumatized Hero: Kerouac’s On the Road and Gandhi’s Railroad Ride
  • Eco-Psychiatry: Why We Need to Keep the Environment in Mind
  • DSM-5: Where Do We Go From Here?
  • Suicidal Behavior: A Separate Diagnosis
  • New Insight Into the Neurobiology of Depression
  • Cultural Psychiatry and the 'No-Chicken' Doctor
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
  • The Moral Struggles of Practicing Psychiatrists
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • NIMH vs DSM 5: No One Wins, Patients Lose
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
SearchMedica SEARCH RESULT

Find peer-reviewed literature and websites for practicing medical professionals

CME on Display
Evidence on Display
Guidelines on Display
Patient Education on Display
Clinical Trials on Display
Practical Articles on Display
Research and Reviews on Display
All "Display" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy